rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
TEC4Home Blood Pressure Randomized Controlled Trial
Status: Not yet recruiting

The goal of this clinical trial is to evaluate the effect of home blood pressure telemonitoring (HBPT) and case management (CM), relative to usual care, for improving blood pressure (BP) control among patients with high blood pressure discharged from the emergency department (ED).

The main question it aims to answer is: Does telemonitoring with case management improve BP control, relative to usual care, for people with high blood pressure discharged from the ED?

Secondary research questions will address:

How do these interventions (telemonitoring and case management) improve medication adherence?
Do these interventions reduce physician and ED visits?
Are these interventions safe?
How do these interventions influence patient experience?

Participants in the intervention group will receive training and use of a home BP telemonitor with tele-transmission function for 12-months plus pharmacist case management to provide behavioral counseling, facilitate medication adherence, review telemonitored BP data, and adjust medications. The control group will receive usual care from their primary care physician and will receive the same home BP monitor and hypertension education.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult patients aged ≥ 18 years of age Elevated triage BP AND increased average BP in three subsequent repeated measurements that are spaced at least 30 minutes after triage (systolic BP ≥ 160 mm Hg or diastolic BP ≥ 100 mm Hg) Own a smart phone Willing to measure and tele-transmit home BP readings  Exclusion Criteria:  Hypertensive emergencies with evidence of end-organ damage, stroke, or acute coronary syndrome Pregnant women Acute intoxication Acute surgical or trauma patients Psychiatrically unstable patients Advanced cognitive impairment Patient requiring admission to hospital Inability to use or care for home BP monitor correctly From nursing home Unstable housing Non-English speaking or no family members who can help translate - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Evaluation of Mobiderm Intimate Bra in the Management of Breast Edema Related to Breast Cancer Treatment
Status: Not yet recruiting

The aim of this exploratory study is to assess the performance and tolerability of the MOBIDERM Intimate Bra in the management of breast edema related to breast cancer treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Females aged 18 years and older. Patients who have undergone conserving surgery for breast cancer. Patients scheduled to undergo radiation treatment of the breast/chest wall within the next 12 weeks after surgery. Patients with a morphology compatible with the proposed sizes of the devices, including bust girth and cup size. Patients who have signed an informed consent form prior to any study intervention. Patients with full legal capacity and enrolled in a social security system or covered by a similar health insurance.  Exclusion Criteria:  Patients with an A cup bra size. Patients with infected or acutely inflammatory skin on the chest. Patients who require chemotherapy during the follow-up period. Pregnant women or women of childbearing age without adequate contraception or in the lactation period. Participation in other clinical trials that impact the primary endpoint. Patients with a known allergy to the investigational device components. Patients with psychiatric, psychological, or neurological disorders that are incompatible with the conduct of a clinical trial. Patients unable to be followed for 12 months. Vulnerable patients, or those subject to a judicial protection measure or unable to provide informed consent freely. - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge
Status: Recruiting

The goal of this clinical trial is to learn about dosing when testing to see if a penicillin allergy label can be removed from adults that had been labeled as "penicillin-allergic" previously. The main question it aims to answer is:

- In penicillin-allergic patients that are at low risk of having an allergic reaction, is a one-dose oral challenge with amoxicillin (a penicillin-based antibiotic) as safe and effective as a two-dose oral challenge?

Participants will, after being identified as having a low-risk penicillin allergy, be administered oral amoxicillin in a controlled setting and then monitored for an allergic reaction. Researchers will compare participants that took one dose of amoxicillin to participants that took two doses of amoxicillin (a small dose and then a larger dose) to see if either group was more likely to develop an allergic reaction.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Expresses interest in participating by calling or filling out information form on study website Reports an allergy to one of the following medications: penicillin VK, penicillin G, amoxicillin, ampicillin, dicloxacillin, flucloxacillin, nafcillin, oxacillin, amoxicillin- clavulanate, ampicillin-sulbactam. Subjects with an unspecified penicillin allergy are also eligible to participate.  Exclusion Criteria:  Penicillin allergy deemed to be more than "low-risk" per PEN-FAST (score ≥ 3 points) History of acute kidney injury (acute interstitial nephritis), severe liver impairment (drug- induced liver injury), serum sickness, or isolated drug fever attributed to a penicillin- based antibiotic Anaphylaxis for any reason in the last year Cognitive impairment where a collateral history could not be obtained and/or patient does not have capacity to consent for themselves Pregnant (self-reported) Any illness or condition that would increase the risk of participation in the study, per the evaluating clinician's judgment Active treatment of or history of acute angle closure glaucoma On H1- or H2-blockers (i.e. diphenhydramine, hydroxyzine, chlorpheniramine, cetirizine, levocetirizine, loratadine, fexofenadine or famotidine, ranitidine, cimetidine, nizatidine, respectively) within 72 hours of initiating direct oral challenge (will be counseled to discontinue prior to testing) Actively receiving greater than stress dose steroid (hydrocortisone >50mg four times a day or steroid equivalent) Actively receiving any antibiotic Relative contraindication: Patients on beta blockers and angiotensin converting enzyme inhibitors (ACE inhibitors) will have an open dialog with the study team regarding the risks and benefits of testing a low-risk penicillin allergy patient. A joint decision will be made based on the patient's preference and the physician's comfort level. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 89 Years - StdAgeList: Adult, Older Adult
Tobacco Exposure and Influencing Factors of Smoking Cessation Among Chronic Kidney Disease Patients
Status: Not yet recruiting

The purpose of this study is to describe the tobacco exposure and characteristics of patients with Chronic Kidney Disease (CKD) who quit smoking, to identify patients' tobacco-related knowledge, attitude, and practice (KAP) and explore the influencing factors of smoking cessation.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Participants aged 18 years or older; Participants with a confirmed diagnosis of Chronic Kidney Disease; Participants were able to speak and read Chinese.;  Exclusion Criteria:  Participants who with psychiatric illness, disorders of consciousness, communication impairments, were unable to communicate effectively; Participants who have acute and life-threatening exacerbations which require urgent treatment; Patients who currently involved in other smoking cessation programs. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Chronic Kidney Disease Patients - SamplingMethod: Non-Probability Sample
Compare the Safety and Effectiveness of Two Different Kinds of Stent System in Intracranial Aneurysms
Status: Recruiting

The primary objective of this trial is to evaluate the safety and efficacy of SINOMED IAS in patients with intracranial aneurysms.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age 18 years to 80 years. Wide-necked (Wide-necked is defined as width ≥ 4 mm or a dome-to-neck ratio < 2), saccular, intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.5 mm and ≤ 5mm. Modified Rankin Scale (mRS) ≤ 2. Subject understands the nature of the procedure, provides voluntary written informed consent prior to the treatment, and is willing to comply with specified follow-up evaluation. The investigators judged the use of stent-assisted coil embolization to be appropriate for the treatment of intracranial aneurysm.  Exclusion Criteria:  Target aneurysm is an aneurysm requiring staged procedure. Target aneurysm that has been previously treated with vascular embolization or surgery. Target aneurysms are fusiform aneurysms, dissecting aneurysms, pseudoaneurysms, blood blister-like aneurysms, infected aneurysms, aneurysms associated with arteriovenous malformations. Hospitalized surgical treatment within 30 days before operation, or planned hospitalized surgical treatment within 6 months after surgery. Acutely ruptured aneurysm within 14 days of enrollment. Hunt and Hess (H&H) scale ≥3. Subject who had Moyamoya disease, arteriovenous malformations, arteriovenous fistulae, intracranial tumors, or intracranial mass lated to target aneurysms. Severe stenosis or tortuosity of intracranial arteries or anatomical anomalies that make it difficult to reach the site of the lesion with device. Platelet count <50*103/mm3 (50*109/L) or any known coagulation deficiency, or International normalized ratio (INR)>3.0. Known hypersensitivity/allergies or contraindication to contrast media, stent components, antiplatelets, anticoagulants. Life expectancy < 1 year, and unable to complete the required follow-ups; Female who was pregnant or breastfeeding, women/men planning to havve children in the next year. Currently enrolled in another investigational device or drug study. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
Additional Effects of Mental Imagery Along With Task Oriented Training on Kinesiophobia in Patients With Stroke
Status: Recruiting

The objective of this study to determine the effect of mental imagery and task oriented training on Kinesiophobia in stroke patients. And to determine the association of Kinesiophobia with gait and balance in stroke patients. Patients will be divided into experimental and control group. Randomized participants will be allocated into control and experimental group. The experimental group will receive 20 minutes of MI training followed by 25 minutes of TOT for a total of 45 minutes, 5 days per week for 6 weeks.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Hemiplegic stroke patients Age above 45 Both genders Patients having score >17 on Tempa Scale of Kinesiophobia Patients of score >21 on Berg Balance Scale  Exclusion Criteria:  • Communication deficits and unable to follow instructions  A history of serious or unstable cardiac condition Severe musculoskeletal problem and unable to stand or walk History of other neurological diseases or unilateral neglect - HealthyVolunteers: No - Gender: All - MinimumAge: 45 Years - MaximumAge: 60 Years - StdAgeList: Adult
Effect of Esketamine on 95% Induction Dose of Remimazolam
Status: Not yet recruiting

As an invasive operation, gastroscopy will cause children's nervousness, anxiety and uncooperative behavior, and even lead to the risk of bleeding and perforation, which will also affect the accuracy of the examination results.The purpose of this study is to explore the influence of different doses of esketamine on the induced dose ED95 of remazolam during gastroscopic placement in children, and to provide theoretical basis for the combined use of remimazolam besylate and esketamine in gastroscopic anesthesia in children.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  with American Society of Anesthesiologists (ASA) physical status I or II#; aged 3#12 years#; children with weight for age within the normal range#; were scheduled to have a gastroscopy;  Exclusion Criteria:  Children who had gastrointestinal,Cardiovascular or endocrine dysfunction; contraindication to preoperative sedation or had a known allergy or hypersensitive reaction to remimazolam and esketamine; recently respiratory infection, mental disorder; other reasons that researchers hold it is not appropriate to participate in this trial. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 3 Years - MaximumAge: 12 Years - StdAgeList: Child
Targeting Subclinical Motor and Cognitive Impairment in Patients With Early Onset Multiple Sclerosis
Status: Recruiting

Our project proposal is based on an individualized rehabilitation approach in patients with early stage relapsing remission (RR) MS. This approach will be based on risk stratification obtained using several clinical and demographic parameters that are not commonly used in clinical practice. This risk score will be obtained from an extensive neuropsychological, psychosocial and physical assessment to which patients will undergo at baseline and at one-year follow-up.The risk score will allow a better stratification of patients' risk of disease worsening/progression and the application of a preventive and personalized strategy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  diagnosis of RRMS based on the 2017 McDonald criteria; age ≥ 18 years; EDSS ≤ 2.0; disease duration ≤ 5 years; verification of MS subtype, duration of disease and EDSS will be accomplished by obtaining a signed consent form for the release of medical information from the treating neurologist.  Exclusion Criteria:  history of relevant psychiatric comorbidities. Severely depressed subjects assessed through the Beck Depression Inventory (scores ≥ 29); relapses or corticosteroid treatment in the 30 days before inclusion; history of substance abuse; presence of non-MS related physical or cognitive impairment that could make the patient unable to complete the study assessments. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Abdominal Massage With TENS on Parasacral Versus Sacral Area on Symptom,Severity & QOL in Chronic Constipation Females.
Status: Recruiting

Constipation is Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections. Patients complaining of constipation may mean different things by the term The frequency of their bowel actions may be less than 'normal', their stools maybe difficult to pass, or they may have a sense of malaise or abdominal discomfort which they attribute to a 'sluggish bowel', though the stool frequency and consistency are apparently normal. Objective of this study is to compare effects of Abdominal massage. withTENSonparasacralversussacralareaonsymptomseverityandqualityoflifein severechronicconstipationamongyoungfemales.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age between 14 -35year Only females Laxatives at least once or more for 2weeks Non pregnant Chronic Constipation more then 6 months  Exclusion Criteria:  Organic dysphasia or secondary constipation caused by laxatives for unrelated conditions. Pregnant females suspected pregnant subjects, as well as those who were breast-feeding Non co-operative patients Female with underlying disease - HealthyVolunteers: No - Gender: Female - GenderBased: Yes - GenderDescription: Females experience more constipation - MinimumAge: 14 Years - MaximumAge: 35 Years - StdAgeList: Child, Adult
Dexmedetomidine and Vasopressin in Septic Shock
Status: Not yet recruiting

Rudiger and Singer suggested strategies for refining adrenergic stress (decatecholaminization). They proposed the use of dexmedetomidine and vasopressin to reduce the catecholamine load during sepsis. The investigators will use vasopressin as the primary vasopressor and a heart rate-calibrated dexmedetomidine infusion in septic shock patients.

The investigators of the current study will use DEXPRESSIN in septic shock patients to investigate the effects of decatecholaminization on in-hospital mortality.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult patients who develop septic shock in whom a vasopressor is initiated to maintain a mean arterial blood pressure (MAP) of ≥65 mmHg in the presence of sepsis (≥2 SIRS criteria plus suspicion or confirmation of infection).  Exclusion Criteria:  Patient refusal or inability to obtain consent Failure of hemodynamic stabilization or hemoglobin <7 g/dL at the time of inclusion Severe cardiac dysfunction [i.e., ejection fraction (EF) <30%] History of heart block or patient on pacemaker Severe valvular heart disease Chronic liver disease (Child-Pugh classification C) Pregnancy Patients with traumatic brain injury - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Atomized Inhalation ICG for Treatment of Congenital Lung Malformations
Status: Not yet recruiting

To investigate the safety and effectiveness of preoperative aerosol inhalation ICG solution for thoracoscopic accurate resection of congenital lung malformations in children.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  children with congenital lung malformations diagnosed by CT or MRI scan  Exclusion Criteria:  1. ages <3 months and >14 years 2. complicated other life-threatening disease; 3. complicated severely pulmonary infection - HealthyVolunteers: No - Gender: All - MinimumAge: 3 Months - MaximumAge: 14 Years - StdAgeList: Child
Effects of IASTM Along With Comprehensive Corrective Exercise Program in Upper Cross Syndrome.
Status: Recruiting

This study will see the effects of IASTM along with comprehensive corrective exercise program in upper cross syndrome through their effects on pain and cervical ranges as well as postural improvement. Our study targets both male and female population. In the reference study only male population was targeted which did not show effects of both techniques on the female population though females have high stress levels which may alter results.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age 18-40 years.  Diagnosed patients with the upper crossed syndrome who have chronic neck pain for more than 3 months. Having neck pain scoring more than 3 on the Numeric Pain Scale were included in this study. Any abnormality in the position and rhythm of the scapula, as measured by the scapular dyskinesis test, having postural changes such as excessive thoracic kyphosis (≥42°), forward head (≥44°) or round shoulder (≥49°) as measured by flexicurve and photogrammetry. Both male and female population will be included  Exclusion Criteria:  The subjects with any previous surgery, any type of Infection Hypersensitive skin Diabetes Mellitus type II Having Traumatic Injury Psychological disorder Manual Therapy contraindication like osteoporosis, infection, Disc- Herniation acute Inflammation, burn scars, closed /non-complicated fractures and open wound. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 40 Years - StdAgeList: Adult
Clock Proteins as a Prognostic Marker for Disease Progression
Status: Not yet recruiting

Asthma is a chronic inflammatory disease of the airways that follows a strong circadian rhythm: Signs of inflammation and symptoms worsen especially in the early morning hours. The molecular circadian clock, which is a complex machinery of transcriptional and translational feedback loops, seems to reflect the inflammatory environment of peripheral blood leukocytes. Therefore, in this observational study we will monitor the molecular circadian clock in patients with severe eosinophilic asthma before and during mepolizumab treatment. Our major goal is to evaluate the potential of the molecular circadian clock to serve as a prognostic marker for disease progression, treatment response or remission in patients with severe eosinophilic asthma. The molecular circadian clock will be monitored in blood and sputum leukocytes from patients with severe eosinophilic asthma before mepolizumab treatment, after 4 month of mepolizumab therapy, and once they reach remission under mepolizumab treatment. Effects will be compared to healthy controls and patients with mild-moderate asthma without mepolizumab treatment.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Written consent of the participant after being informed Age 18-65 Both sexes (male:female ratio of 2:3) Mild-to-moderate asthma, severe eosinophilic asthma according to GINA guidelines and healthy controls  Exclusion Criteria:  Respiratory tract infections during the last 2 months severe comorbidities oral corticosteroids during the last month Shift workers Subjects with sleep disorders and/or receiving sleep medication Pregnant or breast-feeding women Control subjects with atopy and/or allergies - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients with mild-to-moderate or severe eosinophilic asthma and healthy controls will be recruited for this study. Three individual groups within an age-range of 18 to 65 years and a male:female ratio of 2:3 will be studied:  20 age and gender matched healthy controls (1 visit) 20 patients with mild-to-moderate asthma (1 visit)  20-60 patients with SEA  before mepolizumab treatment (visit 1) under mepolizumab treatment for 4 months (visit 2) after reaching remission under mepolizumab treatment (visit 3) - SamplingMethod: Non-Probability Sample
Effect of Neuromuscular Stimulation and Mindfulness Breathing in Patients With Stroke
Status: Recruiting

It is an interventional study in which 60 stroke patients estimated to enroll according to random allocation and divided into two groups. The experimental group will receive neuromuscular stimulation , mindfulness breathing and traditional physiotherapy while the control group will stick to traditional physiotherapy only.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The subject selection will be according to the following criteria: All Patients of this study will be diagnosed as stroke and the diagnosis will be confirmed by computed tomography or MRI (El-Tamawy et al., 2021). Age of patients will be ranged from 50 to 65years (males and females). All patients will be hemodynamically stable. Patients with good cognition that enables them to understand the requirements of the study. Patients with following features: (Abiodun and Dolapo , 2021) FVC : 60-69% (moderate) FEV1 : 60-69% (moderate) FEV1/FVC : 50-59% (moderate) PEF : 50-80% (yellow zone)  Exclusion Criteria:  • The potential participants will be excluded if they meet one of the following criteria:  Patients who cannot follow instructions as sensory aphasia, blindness, dementia, and deafness. Patients with any orthopedic, neurological, or chest disorders that affect trunk muscles control or cause respiratory disorders as COPD. Patients with cognitive and psychiatric disorders. Patients with unstable cardiovascular conditions. Patients with contraindications to neuro electrical stimulation as: Cardiac pace maker. Acute abdominal surgery. - HealthyVolunteers: No - Gender: All - MinimumAge: 50 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult